BRD1

Across TCGA pan-cancer cohorts, BRD1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BRD1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BRD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BRD1 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

LSCC, COAD, and LUAD are the cancer types where BRD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.223	<.001	7	view →
COAD	All	III,IV	−0.296	.029	1	view →
LUAD	Male	II,III,IV	−0.105	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

BRD1–LSCC

Open the LSCC breakdown →